Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 261

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 261
---
, after consultation with outside legal counsel) be managed through the use of customary “clean-room” arrangements or the entering into of any “common interest” Contract or similar Contract), and the Purchaser may offer comments or suggestions with respect to such Transaction Litigation which the Company shall consider in good faith; provided that the Company shall not settle or compromise or agree to settle or compromise any Transaction Litigation without the Purchaser’s prior written consent, which consent shall not be unreasonably withheld, conditioned or delayed. ARTICLE 6 ADDITIONAL COVENANTS REGARDING NON-SOLICITATION

| 6.1 | Non-Solicitation |

| (a) | On and after the date hereof, except as otherwise provided in this Article 6, the Company shall not, and shall 
 cause each of its Representatives not to, directly or indirectly:                                              |

| (i) | make, solicit, assist, initiate, encourage, promote or otherwise facilitate (including by way of furnishing,                                                                                                                                            
 providing access to or disclosing information, books and records, facilities or properties of the Company or a Subsidiary of the Company or entering into any form of written or oral agreement, arrangement or understanding) any inquiry, proposal or 
 offer that constitutes or could reasonably be expected to constitute an Acquisition Proposal;                                                                                                                                                           |

| (ii) | enter into, continue or otherwise participate or engage in or otherwise facilitate any discussions or                                                                                                                                                 
 negotiations with any person (other than the Purchaser, Parent and their respective affiliates and Representatives), or otherwise cooperate in any way with, or assist or participate in, encourage or otherwise facilitate, any inquiry, proposal or 
 offer that constitutes or could reasonably be expected to constitute an Acquisition Proposal, provided that, for greater certainty, the Company may (A) communicate with any person making an unsolicited Acquisition Proposal (and such              
 person’s Representatives) for the purposes of clarifying the terms and conditions of such Acquisition Proposal and assessing the likelihood of its consummation so as to determine whether such Acquisition Proposal constitutes or could             
 reasonably be expected to constitute or lead to a Superior Proposal, (B) advise any person of the restrictions of this Agreement, and (C) advise any person making an unsolicited Acquisition Proposal that such Acquisition Proposal does not        
 constitute a Superior Proposal when the Board of Directors has so determined;                                                                                                                                                                         |

A-38

| (iii) | make a Change of Recommendation; or |

| (iv) | accept, approve, endorse, recommend or enter into, or publicly propose